Next Investors logo grey
  1. Home
  2. Stem Cell Therapy

Stem Cell Therapy

Regeneus and Kyocera ink lucrative deal to commercialise Progenza in $3.5 billion dollar market

Finfeed Archived Aug 11, 2020

Japan is an important market for clinical stage regenerative medicine company, Regeneus Ltd (ASX: RGS), which has just negotiated a license agreement with Kyocera Corporation (Kyocera, TYO:6971) to develop and commercialise Progenza for Knee Osteoarthritis (Progenza OA) in Japan.

Regeneus surges on back of Progenza patent news

Finfeed Archived Mar 23, 2020

The US Patent and Trademark Office (USPTO) has issued a notice of allowance for issuance of a new key patent for clinical-stage regenerative medicine company Regeneus Ltd's (ASX: RGS) lead stem cell platform technology Progenza.

Can This ASX Junior Surge Through the Pain Barrier?

Next Investors Archived Mar 02, 2020

Biotech company Regeneus (ASX:RGS) is a regenerative medicine company, and the therapy is a novel stem cell therapy.

Join Our
Mailing List